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Abstract
Background: A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable
0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema.
Results: Data are presented from eight patients (11 eyes) with non-infectious uveitic macular edema who were treated
with a 0.19-mg fluocinolone acetonide implant. Nine out of 11 eyes were pseudophakic prior to implantation
of fluocinolone acetonide implant, and both phakic eyes required cataract surgery during the follow-up
period (the median follow-up was 19 months; range, 8–42 months). Effectiveness and safety were assessed
from changes in central retinal thickness (measured using spectral domain optical coherence tomography),
corrected distance visual acuity, uveitic activity, and intraocular pressure.
The main outcome measures were changes in central retinal thickness, corrected distance visual acuity, uveitic
activity, and intraocular pressure. In 11/11 eyes, central retinal thickness improved between months 1 and 3.
The mean maximum decrease of central retinal thickness throughout the follow-up period was 168 ± 202 μm
(± standard deviation). Nine out of 11 eyes showed an improvement in corrected distance visual acuity
(between + 1 and + 8 lines), and 2/11 eyes lost corrected distance visual acuity (− 1 and − 3 lines, respectively). Nine
out of 11 eyes presented with inactive inflammation during the follow-up period, and in 1/11 eyes, there was a relapse
at month 42. Four out of 11 eyes presented with a relapse of macular edema between months 3 and 8. The mean
increase in intraocular pressure was 2.1 ± 4.7 mmHg. Nine eyes were pseudophakic prior to implantation of
the injectable fluocinolone acetonide intravitreal implant. Both phakic patients developed a cataract that was
treated with cataract surgery in the follow-up period.
Conclusions: In this small case series with long-term follow-up, treatment of non-infectious uveitic macular
edema with the injectable fluocinolone acetonide implant was associated with improved central retinal thickness and
corrected distance visual acuity and a manageable safety profile. The advantage of this device is the long-term drug
release and the fact that it can be injected into the vitreous as a minor surgical procedure, which is in contrast to other
treatment options.
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Introduction
Inflammatory cystoid macular edema is a result of the
breakdown of the blood-retina barrier and one of the main
reasons for loss of vision in patients with non-infectious
uveitis [1]. There are a variety of different local and
systemic treatments available to treat uveitis, which help
to reduce levels of inflammation and to resolve macular
edema [2]. Although a broad range of different
corticosteroid-sparing treatments is available, used to
avoid the well-known steroid side effects, corticosteroids
are still an important component in the treatment of uve-
itis because they are particularly effective in alleviating the
inflammation associated with non-infectious uveitis. The
wide spectrum of uveitis requires an individualized treat-
ment approach and often combined therapy in some
cases, particularly in patients with intolerance to systemic
treatments where localized treatments are administered.
This is an area where new corticosteroid-based implants
have gained growing interest as their sustained effect may
help to stabilize the disease activity. The dexamethasone
implant (OZURDEX) is a short-acting corticosteroid last-
ing up to 6months, and it has been used successfully in
the treatment of uveitis over the last few years [3]. The
surgically implanted 0.59-mg fluocinolone acetonide im-
plant (RETISERT) is FDA approved but has no EU license.
It has also been shown to be effective in the treatment of
uveitis [4], but has been associated with higher risks, e.g.,
raised intraocular pressure and dislocation of the implant
[5]. The 0.19-mg fluocinolone acetonide intravitreal im-
plant (FAc implant; ILUVIEN; Alimera Sciences Inc., Al-
pharetta, USA) is designed to provide a sustained release
of 0.2 μg/day of fluocinolone acetonide for up to 3 years.
The implant consists of a non-biodegradable polymer with
a length of 3.5 mm and a diameter of 0.37mm. The Fluo-
cinolone Acetonide for Diabetic Macular Edema (FAME)
studies showed the FAc implant was effective in patients
with diabetic macular edema (DME) and is now licensed
for this indication [6]. As this implant has been shown to
be effective in DME, it is hypothesized to be effective in
treating other inflammatory based conditions such as
non-infectious uveitis. The injectable FAc implant has
been successfully used in the treatment of patients with
non-infectious uveitis in a 2-year follow-up study [7]. Our
retrospective observational study therefore aimed to
evaluate results from our clinic where it has been used
off-label to treat non-infectious uveitic ME since 2013.
Methods
This study encompasses 11 eyes from 8 patients with
non-infectious uveitic ME that were treated with the
FAc implant in our department. A retrospective review
of patient data was conducted based on clinical exami-
nations obtained between 2013 and 2017 in the Depart-
ment of Ophthalmology at the University of Heidelberg.
The analysis involved the measurements of corrected
distance visual acuity (VA), central retinal thickness
(CRT) measured using spectral domain optical coher-
ence tomography (SD-OCT; Heidelberg Engineering),
intraocular pressure (IOP) measured using Goldmann
applanation tonometry, and signs of intraocular inflam-
mation in the anterior and posterior segment of the eye
according to the inflammation grading scheme defined
by the SUN Working Group [8]. In addition, the
follow-up data was analyzed with regard to serious ad-
verse events and safety.
Results
The median patient follow-up period was 19months
(range 8 to 42 months). Four of the patients (5 eyes) had
been diagnosed with uveitis intermedia, three patients (4
eyes) had idiopathic intermediate uveitis, and one pa-
tient (one eye) suffered from intermediate uveitis associ-
ated with multiple sclerosis. Two patients had posterior
uveitis—the first patient was diagnosed with acute zonal
occult outer retinopathy (AZOOR; one eye) and the sec-
ond patient was diagnosed with MCP (Multifocal Chor-
oiditis and Panuveitis) (two eyes). One patient (two eyes)
was diagnosed with rheumatoid arthritis-associated
panuveitis and one patient (1 eye) was diagnosed with
idiopathic vasculitis. Nine eyes were pseudophakic
(81.8%), and two eyes (18.2%) were phakic prior to the
treatment with the injectable FAc implant. Table 1 sum-
marizes patient demographics, diagnosis, duration of
CME, and treatments before the application of the im-
plant. Five patients were female (62.5%), and three were
male (37.5%). The median age of the patients was 49
years (range 25 to 65 years). The median duration of
chronic macular edema (i.e., receiving regular therapy)
before treatment with FAc implant was 36months
(range 18 to 108 months). Prior to the treatment with
FAc implant, seven of the patients (ten eyes) had under-
gone multiple local steroid treatments with periocular or
subconjunctival injection of triamcinolone. All eight pa-
tients (11 eyes) had been treated with multiple dexa-
methasone implants before the FAc implant was
injected. Five patients were treated with systemic im-
munosuppressive therapy (cyclosporine, methotrexate,
prednisolone, mycophenolate, or combinations) when
they received the injectable FAc implant. One of the eyes
had undergone vitrectomy and membrane peeling prior
to receiving the FAc implant.
Central retinal thickness (CRT)
All of the eyes presented with an initial improvement of
CRT, and this was observed in 8 eyes in the first
3 months after being treated with the FAc implant.
Mean CRT prior to treatment with the FAc implant was
440 μm (range 243 to 930 μm), and the mean maximal
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decrease in CRT after treatment was 168 μm. Eight eyes
(72.7%) presented with a completely dry macula during
the follow-up. At the first follow-up point, 1 to 3 months
after injection (n = 7), there was a mean decrease in CRT
of 81 μm (range 10 to 445 μm) and five of the eyes pre-
sented with a dry macula. Four to 6 months after the in-
jection (n = 6), there was a mean decrease in CRT of
220 μm from baseline levels. Not all of the patients pre-
sented for early follow-up examinations in our clinic.
One patient was examined for the first time after
6 months, and CRT had decreased by 247 μm with
complete resolution of ME (no. 6). Another patient was
examined 10 months after injection of FAc implant
when CRT had decreased by 31 μm and the macula was
completely dry (no. 4, OS). The longest first follow-up
time point was 33 months after injection of the FAc im-
plant by which time CRT had decreased and the macula
was dry (no. 5, OS). In four cases, CRT increased during
the follow-up period. Indeed, one of these patients had a
reduction in CRT of 130 μm 1 month after the injection
of the FAc implant, but relapsed by month 3 and CRT
increased by 81 μm. This was explained partly by the
additional presence of an epiretinal membrane (no. 1,
OS) with traction in the macular region aside from the
uveitic activity. Another case (no. 3) showed a marked
initial response to treatment and CRT decreased by
445 μm at month 3 and 698 μm at month 4. There was,
however, a relapse of the CRT by month 6 and CRT in-
creased to 610 μm. Nevertheless, there was still a consid-
erable reduction with respect to baseline CRT which
was 930 μm. In another case (no. 7), 4 months after the
FAc implant was administered, CRT decreased by
168 μm from baseline and there was only minimal
intraretinal fluid. By month 8, CRT increased by 118 μm.
One of the phakic patients (no. 8) showed a marked re-
duction in macular edema 6months after treatment with
the FAc implant at which time CRT had decreased by
247 μm and the macula was dry (and then sustained
through to month 8). Following cataract surgery, con-
ducted in combination with a pars plana vitrectomy and
peeling of the epiretinal membrane, the patient pre-
sented with a relapse of ME.
Visual acuity (VA)
In our cases, a reduction of CRT was associated with an
improvement of VA. Six months after the treatment with
Table 1 Overview of the diagnosis, duration of CME, and ocular and systemic treatment of the patients prior to FAc implant
No. of eye Gender,
age
(years)
Diagnosis Systemic treatment Duration of chronic
ME under therapy
Previous ocular treatments
1 OD/OS M, 60 Panuveitis, rheumatoid
arthritis
Cyclosporine, methotrexate,
prednisolone
36 months Multiple triamcinolone
periocular, multiple
dexamethasone intravitreal
2 OS M, 50 Intermediate uveitis Mycophenolate 36 months Multiple triamcinolone
periocular and subconjunctival,
multiple dexamethasone
intravitreal
3 OS F, 25 Posterior uveitis, acute
zonal outer occult
retinopathy (AZOOR)
None currently, previously
mycophenolate (stopped
because of intolerances)
6 years Multiple dexamethasone
intravitreal, bevacizumab (1×)
intravitreal
4 OD/OS F, 48 Intermediate uveitis None currently, previously
methotrexate and
mycophenolate, (mycophenolate
stopped when diagnosed
with malignant melanoma)
4 years Multiple triamcinolone
periocular and intravitreal,
multiple
dexamethasone intravitreal
5 OD/OS F, 45 Posterior uveitis, multifocal chorioretinitis
and panuveitis (MCP)
Azathioprine 6 years Multiple triamcinolone
periocular and intravitreal,
multiple
dexamethasone intravitreal
6 OD M, 50 Intermediate uveitis,
multiple sclerosis
Previously: high-dose
corticosteroid therapy,
interferon beta, fingolimod
Currently: rituximab IV every
6 to 9 months
18 months Triamcinolone periocular (2×),
dexamethasone intravitreal (2×)
7 OD F, 37 Intermediate uveitis Cyclosporine, methotrexate 9 years Multiple triamcinolone
subconjunctival, multiple
dexamethasone intravitreal
8 OD F, 65 Idiopathic vasculitis None 25 months Triamcinolone periocular (1×),
multiple dexamethasone
intravitreal (3×)
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the injectable FAc implant, nine of the eyes (81.8%)
gained at least one line of VA (1 eye gained 8 lines, 2
eyes gained 3 lines, 2 eyes gained 2 lines, 4 eyes gained 1
line). As our patients suffered from chronic ME prior to
treatment with the FAc implant, a full recovery of VA
was not observed in all cases. Indeed, a relapse of ME
led to a decrease in VA in two patient cases. Also, two
phakic eyes experienced a decline in VA during the
follow-up period, and in one of these eyes, cataract re-
moval led to an 8 line (from 20/160 to 20/25) improve-
ment in VA.
Uveitis activity
During the follow-up period, the parameters of uveitis
activity (AC-cells, corneal precipitates, vitreous haze,
and cells) were recorded and analyzed. Nine of the eyes
(81.8%) presented with an improvement or inactive in-
flammation. One of the eyes (9.1%) failed to respond to
treatment and at 3 months presented with macular
edema and an increase in vitreous haze (no. 1, OS).
Duration of the effect
In three patients, the duration of the FAc implant did
not last 3 years, and following an initial response, there
was a thickening of the macula at months 3, 6, and 8
(no. 1, no. 3, and no. 7, respectively) without a clear
cause (e.g., surgery). In a further case, however, relapse
of macular edema and vitreous haze occurred 42months
after initial treatment. Responses were maintained in the
remaining six eyes (five patients) with stable findings
noted at months 16, 19, 32, 33, 35, and 40.
Adverse events
Both phakic patients developed a cataract after treatment
with the FAc implant and required surgery to remove
it (Table 2). One of the patients was treated successfully
with cataract surgery and went on to experience an im-
proved VA and a dry macula. This patient was treated
with prophylactic periocular injection of triamcinolone
prior to surgery. The second phakic patient underwent
cataract surgery in combination with pars plana vitrec-
tomy and membrane peeling, but developed a macular
edema after treatment that required additional therapy.
The mean increase in IOP in the whole group was 2.1 ±
4.7 (mean ± standard deviation). None of the patients (n =
0) presenting with raised IOP required additional medica-
tion or surgery (Table 2). Moreover, no patients presented
with major ophthalmic complications (e.g., endophthalmi-
tis, hypotonia, retinal detachment or dislocation of the im-
plant) and no adverse systemic side effects were reported.
Individual cases
Case no. 1
A male patient aged 60 years with idiopathic non-infec-
tious panuveitis, including significant macular edema in
both eyes, received an FAc implant in the right eye and
a subsequent FAc implant in the left eye 1 month later.
On the day of the insertion, no AC-cells, vitreous haze,
or retinal or choroidal lesions were observed. The
1-month follow-up showed a remarkable reduction of
CRT from 599 to 320 μm and an improvement of VA
from 20/40 to 20/20 in the right eye. The further
follow-ups in the right eye showed continuous stable
findings in terms of clinical and OCT examinations up
until month 19 (Fig. 1). In the left eye, the 1-month
follow-up showed a reduction in CRT from 652 to
522 μm, but further follow-ups (3, 4, and 7 months)
showed a continuous increase in CRT (up to 642 μm)
and signs of inflammation in the vitreous and anterior
segment. This was identified by Tyndall, KP, vitreous
haze, and vitreous cells which required additional treat-
ment with systemic and local steroids (i.e., subconjuncti-
val TCA at month 7) which led to a reduction of CRT
from 642 to 550 μm and an improvement in VA (20/63)
as well as remission of intraocular inflammation. Parallel
to therapy with the FAc implant, subconjunctival TCA,
and systemic steroids, the patient was treated systemic-
ally with a stable dose of MTX and CSA. The follow-ups
around month 12 showed stable findings in both eyes
and so the dose of MTX was reduced from 20mg/week
to 15 mg/week. The different response of both eyes to
the FAc implant was explained by the presence of an
epiretinal membrane in the left eye with partial persist-
ence of the edema resulting from traction of the epiret-
inal membrane.
Case no. 2
One 50-year-old female patient with idiopathic non-infec-
tious uveitis intermedia in the left eye was treated with
FAc implant. The follow-up (at month 3 and 10) showed a
reduction of the CRT from 297 μm (at baseline) to 285 μm
at month 10 and that the intraretinal cystoid edema had
receded. A reduction of AC cells and vitreous haze was
also evident. Anatomical improvements were accompan-
ied by a slight improvement in VA from 20/40 to 20/32.
Sixteen months after receiving the FAc implant, the pa-
tient presented with stable findings and normal intraocu-
lar eye pressure.
Table 2 Overview of complications
Complications/surgery Percentage and number of patients
IOP increase > 5mmHg 27.3% (n = 3/11)
IOP increase > 10mmHg 9.1% (n = 1/11)
IOP increase > 30mmHg 0% (n = 0/11)
IOP lowering surgery 0% (n = 0/11)
Cataract surgery 18.2% (n = 2/11)
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Case no. 3
One patient had a diagnosis of AZOOR (female, 25
years), and the left eye was treated with the FAc implant.
At the 3-month follow-up time point, there was a re-
markable reduction of the ME/CRT from 930 to 485 μm
and an improvement in VA from 20/400 to 20/160, and
intraocular pressure was low/normal. No AC cells or vit-
reous haze prior or after the treatment were observed.
The 4-month follow-up showed a further improve-
ment in ME with a CRT of 232 μm with an increase
of the eye pressure to 19 mmHg and VA declining
slightly to 20/200. Unfortunately, the 6-month
follow-up showed an increase in CRT to 610 μm,
which required additional therapy (subconjunctival in-
jection of triamcinolone). At month 8, the CRT de-
creased to 421 μm, VA was stable, and intraocular
pressure was slightly elevated at 22 mmHg.
Case no. 4
A 48-year-old female patient suffering from bilateral
idiopathic non-infectious uveitis intermedia with diffuse
ME and pseudophakia received a FAc implant in both
left and right eyes. On the day of insertion, AC cells (1+)
and vitreous haze (0.5+) were observed. The right eye
was treated first and the 3-month follow-up showed a
remarkable improvement in VA from 20/400 to 20/63
and a reduction in CRT from 243 μm to 215 μm, which
was accompanied by a reduction of inflammatory signs
in the AC and the vitreous. Up to almost 3 years after
the injection of FAc implant, the patient presented with
stable findings (i.e., a dry macula and low normal eye
pressure) and no signs of inflammatory activity in the
anterior or posterior segment of the eye. Therapy with
mycophenolate (Myfortic) had to be stopped because of
the diagnosis of malignant melanoma 4months after the
FAc implant had been injected in the right eye. From
month 14, the right eye had no additional local therapy
with topical steroids. In the left eye, the FAc implant
was injected about 7 months after the right eye had
started treatment with the FAc implant. The VA was
stable (20/63) after treatment. During follow-up, the
cystoid ME receded and the CRT decreased from
280 μm to 249 μm at around month 10 and remained
stable up to the last follow-up at month 35. The vitreous
Fig. 1 Case no. 1. a OD baseline examination: CRT 599 μm, VA 20/40. b OD 1-year follow-up: CRT 311 μm, VA 20/25
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cell count decreased (to zero cells), and there were no
signs of inflammation in the left eye despite treatment
with systemic mycophenolate (Myfortic) being stopped.
Case no. 5
A female patient aged 45 years with bilateral multifocal
chorioretinitis and panuveitis (MCP) was treated with a
single FAc implant in both eyes. On the day of insertion,
no AC-cells, vitreous haze, or retinal or choroidal lesions
were observed. The right eye, which was treated first,
showed a decrease in CRT from 302 to 275 μm at month
1 with stable eye pressure and no signs of inflammatory
activity in the anterior or posterior segment of either
eye. The patient described the subjective and objective
findings during the follow-up as stable and calm. Forty
months after the injection of the FAc implant in the
right eye and 33 months after it was injected into the left
eye, there was a dry macula and no signs of new chorior-
etinal lesions.
Case no. 6
A 50-year-old male patient with uveitis intermedia asso-
ciated with multiple sclerosis, and cataracta subcapsu-
laris posterior incipiens was treated with a FAc
implant (right eye). At month 4, there was a remarkable
reduction in CRT from 440 to 247 μm, a dry macula, the
vitreous cell count was reduced, there were no signs of
inflammatory activity in the anterior or posterior seg-
ment of the eye, and there was an improvement of VA
from 20/50 to 20/40. The patient presented with stable
findings until month 22. Prior to and in parallel to treat-
ment with the FAc implant, rituximab was delivered sys-
temically every 6 to 9 months. The follow-up after 31
months showed a progression of cataract with a reduc-
tion of the visual acuity (20/160) on the right eye. The
patient was treated successfully with cataract surgery
and went on to experience an improved VA (20/25) and
a dry macula.
Case no. 7
A female patient aged 37 years with uveitis intermedia and
macula edema was treated with a FAc implant (right eye).
On the day of insertion, no AC-cells, vitreous haze, or
new chorioretinal lesions were observed. At month 1,
CRT decreased from 488 to 407 μm and there was a slight
improvement in VA from 20/40 to 20/32. This was ac-
companied by stable eye pressure and no signs of inflam-
matory activity in the anterior or posterior segments of
the eye. At the 8-month follow-up time point, there was a
slight relapse of the macular edema (CRT was 438 μm).
Prior to and in parallel to treatment with the FAc implant,
MTX was administered systemically.
Case no. 8
A female patient with idiopathic non-infectious vasculitis
with ME received a single FAc implant in her right eye,
which was phakic. On the day of insertion, no AC-cells,
vitreous haze, or new chorioretinal lesions were observed.
At the 3-month follow-up, there was a decrease in CRT
from 536 to 289 μm. No new chorioretinal lesions were re-
ported during the follow-up examinations (up to month
8); however, the right eye did develop a cataract. Because
of an additional epiretinal membrane the patient had a
cataract surgery in combination with pars plana vitrec-
tomy and membrane peeling. After the surgery, ME devel-
oped and required anti-inflammatory therapy in addition
to the FAc implant.
Discussion
Locally delivered steroids have been shown to be effect-
ive in the treatment of non-infectious uveitic ME (i.e.,
the dexamethasone implant). The injectable FAc implant
allows a low dose of steroid to be delivered up to 3 years.
It can be injected directly into the vitreous unlike other
fluocinolone acetonide based implants (e.g., Retisert). In
this study, we aimed to determine the effectiveness and
safety of the injectable FAc implant in eyes with inflam-
matory cystoid ME. The results of this case series
showed that the intravitreal injection of the FAc implant
resulted in a decrease of CRT that was usually accom-
panied by an improvement in VA and a reduction in
uveitis activity. The effect of the treatment was relatively
quick with onset occurring between 1 and 3 months.
Cases also show that over a relatively long period of
time, improvements were sustained (2 eyes > 16 months,
5 eyes > 30months) and support the long-acting nature
of the implant. The extended duration of effect with re-
spect to previously used therapies led to greater patient
satisfaction and also a lower rate of consultations with
the uveitis specialists. In our examinations, FAc implant
presented with an acceptable risk profile and no remark-
able increases in IOP were reported. However, both
phakic patients developed a cataract requiring surgery
during the follow-up period. The FAc implant led to an
initial decrease in CRT in all patients. Nevertheless, in
some patients, a relapse of ME was reported. In these
cases, the dexamethasone implant was successfully used
and might indicate that a higher corticosteroid dose may
be required in these cases. In one of these patients, a re-
lapse can be explained partly by the additional presence
of an epiretinal membrane (no. 1) with traction in the
macular region aside from the uveitis activity. Another
one of these patients (no. 3) was quite young (25 years)
with a high uveitis activity. In these cases, a combination
with other treatment options might need to be consid-
ered. The FAc implant provided long-term improvement
of macular edema and retreatment needs to be
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considered and planned as they approach 3 years of
follow-up. This is particularly important to reduce any
potential losses in VA due to reactivation of uveitis.
Local application of intravitreal corticosteroids is an
important strategy in the treatment of non-infectious
uveitis. This is especially true in unilateral cases of uve-
itis where local injections are convenient and often lead
to fast responses whilst avoiding the systemic side effects
of corticosteroids or supplemented immunosuppression.
Locally delivered corticosteroids (periocular, subconjunc-
tival or intravitreal injection, or surgical implantation)
have shown remarkable results in a number of past stud-
ies. Indeed, in a multicenter retrospective cohort study in-
volving 914 patients (1192 eyes), receiving at least one
periocular corticosteroid injection (predominantly 40-mg
triamcinolone acetonide) reported periocular injections
were effective in treating active intraocular inflammation
and also reversing declines in VA as a result of DME.
Cataract and ocular hypertension occurred in a minority
of the cases [9]. As periocular injections only last about 6
weeks, chronic diseases demand longer-lasting options.
The Huron study group published their findings in which
the dexamethasone intravitreal implant had been used to
treat non-infectious intermediate and posterior uveitis [3].
This was a 26-week trial, and eyes with non-infectious
intermediate or posterior uveitis and patients were ran-
domized to receive a 0.7-mg dexamethasone implant (n =
77), 0.35-mg dexamethasone implant (n = 76), or a sham
procedure (n = 76). Significantly more eyes in the dexa-
methasone implant-treated arms experienced improved
VA than in the sham-treated arm. Moreover, the propor-
tion of eyes with a vitreous haze score of 0 at week 8 was
significantly higher in the implant groups than in the
sham group. The percentage of eyes with intraocular pres-
sure of ≥ 25mmHg was 7.1% for the 0.7-mg dexametha-
sone implant, 8.7% for the 0.35-mg dexamethasone
implant, and 4.2% for the sham (P > 0.05 at any visit). The
incidence of cataract reported in the phakic eyes was 15%
(9 of 62 eyes) in the 0.7-mg dexamethasone implant arm,
12% (6 of 51 eyes) in the 0.35-mg dexamethasone implant
arm, and 7% (4 of 55) in the sham arm (P > 0.05). The au-
thors concluded that a single dexamethasone intravitreal
implant significantly improved intraocular inflammation
and VA for up to 6months in patients with non-infectious
intermediate or posterior uveitis. The dexamethasone im-
plant has also been successfully used in the treatment of
persistent uveitic ME [10].
Longer-acting corticosteroids have been developed
such as the surgically placed fluocinolone acetonide im-
plant (Retisert) which was approved by the US FDA in
2005. Its efficacy is being tested in the Multicenter Uve-
itis Steroid Treatment (MUST) Trial [11]. This study in-
volves 215 patients with intermediate, posterior, or
panuveitis that have been treated for 7 years with either
a surgically placed intravitreal fluocinolone acetonide
implant or systemically administered corticosteroids
supplemented with immunosuppression. Follow-up was
conducted in tertiary uveitis subspecialty practices. Two
hundred fifty-five patients were enrolled in the MUST trial
between 2005 and 2008. After 7 years, results showed that
the mean change in VA favored systemic therapy (+ 7.2
letters; 95%CI, 2.1–12). A closer look at the data, however,
shows that VA in the two groups was not significantly
different during the first 5 years. The implant group pre-
sented with better results with respect to the effect on uve-
itis activity and macular edema, but VA results were worse
in this group at year 7 due to reactivation of uveitic activity.
This seems to be caused by irreversible chorioretinal lesions
in the implant group and may possibly relate to severe in-
flammatory recurrences. It is also worth remembering that
the expected duration of the implant was up to 3 years.
So far, the injectable FAc implant is only indicated for
the treatment of DME. The FAME trials investigated the
safety and efficacy of the FAc implant [12]. This was a
multicenter clinical trial involving 375 DME subjects
treated with low-dose (0.2 μg/day) and 393 subjects
treated with high-dose (0.5 μg/day) fluocinolone acetonide
intravitreal implant. Both doses of the FAc implant signifi-
cantly improved BCVA versus a sham control (n = 185) up
to 3 years after treatment was initiated [13]. There was a
higher rate of cataract surgery in subjects treated with the
FAc implants, but interestingly, the VA results after cata-
ract removal were similar to those that were pseudophakic
when recruited into the study. Elevated IOP surgery rates
were 4.8, 8.1, and 0.5% in low, high, and sham groups.
Comparing the relative risk-to-benefit profile, the authors
considered the low-dose intravitreal implant to be the bet-
ter choice as similar efficacy outcomes could be achieved
with a lower rate of adverse events.
The injectable FAc implant has also been successfully
used in the treatment of patients with non-infectious uve-
itis in a 2-year follow-up [7]. Data from 11 eyes (11 partic-
ipants) were randomized to receive either a low- or a
high-dose version of a FAc implant. The VA improved sig-
nificantly by year 2 and none of the study eyes experi-
enced a relapse of the inflammation. Six participants
continued to receive systemic medication after implant-
ation and the dosage was reduced in four of them. Five of
11 eyes had received an average of 1.6 periocular triamcin-
olone acetonide injections in the 12months preceding im-
plantation. The most common adverse event was elevated
IOP. The authors concluded that the implant is a promis-
ing approach in patients with non-infectious intermediate
and posterior uveitis.
Limitations
There are several study limitations that need to be men-
tioned. The data comes from a small, heterogeneous series
Weber et al. Journal of Ophthalmic Inflammation and Infection             (2019) 9:3 Page 7 of 9
of patients. There was no randomization and no compari-
son to a control group (other treatment or sham injec-
tion). As the data were analyzed retrospectively, the
duration of follow-up was not prespecified. Examinations
of the patients were individually planned and executed, in
some cases, mainly at the local ophthalmologist’s clinic.
This fact, however, can also be seen as a positive effect of
the FAc implant that reduced inflammation in these eyes
and specialist consultation with a uveitis center was not
required. Prior and parallel to the therapy with the FAc
implant, five patients (7 eyes) received systemic therapy
due to an underlying systemic disease and this may have
influenced outcomes as in the majority of cases systemic
therapy remained unchanged. Lastly, larger, randomized
clinical trials are required to support these findings.
Conclusions
In this small case series with long-term follow-up, treat-
ment of non-infectious uveitic ME with the injectable
FAc implant was associated with improved CRT and VA,
as well as reduced uveitis activity and a manageable
safety profile but a risk of cataract development. The ad-
vantage of this device is the long-term drug release and
the fact that it can be injected into the vitreous using a
simple surgical injection technique.
Addendum
The fluocinolone acetonide intravitreal implant is com-
mercially available in Europe, the Middle-East and the
USA (ILUVIEN, marketed by Alimera Sciences) for
treating DME, and recently received FDA approval in
the USA (YUTIQ, marketed by EyePoint Pharmaceuti-
cals) as a treatment for non-infectious uveitis affecting
the posterior segment of the eye (NIU-PS).
Clinical Indications
ILUVIEN
a) In Europe, ILUVIEN is indicated for the treatment
of vision impairment associated with chronic diabetic
macular oedema, considered insufficiently responsive to
available therapies;
b) In the USA and Middle-East, ILUVIEN is indicated
for the treatment of diabetic macular edema in patients
who have been previously treated with a course of
corticosteroids and did not have a clinically significant
rise in IOP.
YUTIQ
Indicated in the USA for the treatment of chronic
non-infectious uveitis affecting the posterior segment
of the eye.
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